Researchers are studying RSO-021, an experimental drug delivered into the space surrounding the lung, as a possible treatment approach for pleural mesothelioma. It targets peroxiredoxin 3 (PRX3), an antioxidant enzyme involved in protecting cells from oxidative stress.
RSO-021 is investigational and is not an FDA-approved treatment for mesothelioma. The available research does not establish a survival benefit or superiority over standard care.
What has been published in a peer-reviewed journal?
A July 14, 2026 study in Nature Communications described laboratory investigations and an early Phase I clinical study. Fifteen participants with malignant pleural disease received RSO-021 in the initial study population, including 12 with pleural mesothelioma. In the reported 90-mg group, the investigators described disease control in 67% at 12 weeks. This was an early, small study, not a randomized demonstration of improved survival.
How is RSO-021 given?
In the clinical study, RSO-021 was administered directly into the pleural space through an indwelling pleural catheter. That differs from an oral medication or an intravenous infusion. Catheter-related complications, breathing symptoms, and other adverse events remain important safety considerations.
What does the later MITOPE program add?
The broader Phase I/II MITOPE trial, NCT05278975, is listed as completed in its clinical-trial record. A separate October 2026 conference analysis has been reported, but its complete original poster and detailed tables were not independently confirmed for this article. Accordingly, we are not presenting its reported response counts, survival comparisons, or adverse-event percentages as established findings here. The published July findings and the broader trial's reported enrollment should not be treated as the same analysis population.
What should patients understand?
Disease control, partial tumor response, and improved survival are different outcomes. Small, nonrandomized studies can help researchers select doses and identify signals worth testing, but they cannot establish that a new treatment is better than established options. Patients considering investigational therapy should discuss clinical-trial availability and individual medical circumstances with their oncology team.
Original sources and H&S background
- Nature Communications — July 14, 2026 peer-reviewed research
- ClinicalTrials.gov — MITOPE, NCT05278975
- RS Oncology — July 2026 research announcement
- H&S mesothelioma treatment information
- H&S Mesothelioma News Desk
Medical information notice: Humpleby & Strauss, P.C. is a law firm, not a medical provider. This article is educational and is not medical advice. Editorial standards.